Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The pharmaceutical powerhouse continues to remunerate its shareholders. It declared a fresh quarterly dividend.

Why Eli Lilly Stock Jumped by 4% Today

INDIANAPOLIS , May 6, 2024 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock. The dividend is payable on June 10, 2024, to shareholders of record at the close of business on May 16, 2024.

Lilly Declares Second-Quarter 2024 Dividend

Examine the evolution of Lilly's (LLY) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Lilly (LLY) Reliance on International Sales: What Investors Need to Know

Eli Lilly and Co. NYSE: LLY reported strong Q1 2024 earnings, causing shares to soar towards all-time highs initially, but a sell-the-news reaction triggered in the following days. The medical sector biopharmaceutical giant continues to gain from the GLP-1 drug weight loss trend that's taken the mainstream by storm.

Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon

Alphabet

Alphabet just announced its first-ever dividend and a whopping $70 billion stock buyback. Eli Lilly's blockbuster weight-loss treatment is changing its customers' lives -- and delivering fortune-building gains to its shareholders.

2 Top Stocks That Could Make You Richer in 2024

Coca-Cola

Toronto-Dominion Bank

Eli Lilly not only has an impressive track record for paying dividends but has also doubled its payouts in just five years. Coca-Cola has a dividend growth streak that spans 62 years.

3 Super-Safe Dividend Stocks That Have Been Making Recurring Payments for 130+ Years

Pfizer

Vertex Pharmaceuticals

It's always a good time to buy shares of Eli Lilly. Pfizer is undervalued and underrated.

3 No-Brainer Stocks to Buy in May

Eli Lilly's Mounjaro is a diabetes medication that competes with Novo Nordisk's Ozempic. Lilly is making strides in the weight-loss market, and its newest treatment may be a smashing success.

Move Over, Mounjaro. Eli Lilly Has Another Blockbuster in the Making

Novo Nordisk

The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Eli Lilly stock is way up over the past year, but analysts who follow the company think it still has more upside. Sales of Eli Lilly's weight-management treatment are soaring and could climb much higher.

Eli Lilly Raised Its Outlook. Is the Stock a Buy Now?

Amgen

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide

The pharmaceutical sector mainstay has attracted much attention with a recently approved drug. It also posted impressive quarterly results at the end of April.

1 Wall Street Analyst Thinks Eli Lilly Stock Is Going to $892. Is It a Buy?

Eaton

Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.

Earnings Season: 3 Companies Boosting Guidance

Broadcom

Companies have clearly defined goals: to grow their customer base, brand power, and global influence, compete with giants like Nvidia (NASDAQ: NVDA ), Meta (NASDAQ: META ), Apple (NASDAQ: AAPL ), Microsoft (NASDAQ: MSFT ) and Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ), and join the shortlist of trillion-dollar stocks.  While this sounds great, reaching a trillion-dollar market cap is a tough mountain to climb.

3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now

Lilly's Mounjaro and Zepbound should have tremendous growth ahead. The company could have even better weight loss drugs in its pipeline.

Here's Why Eli Lilly Stock Remains a Screaming Buy

Identifying the next trillion-dollar market is a serious challenge. Reaching a trillion-dollar market cap symbolizes more than just financial success; it reflects a company's profound global impact, expansive customer base, and enduring brand influence.

3 stocks poised for trillion-dollar valuations to consider today

Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial supply shortages ease.

Wegovy, Mounjaro prices cut as British pharmacies compete for weight-loss patients

American Express

Domino's Pizza

McDonald's

Netflix

We're a little more than halfway through first-quarter earnings season, so now is the time to review this earnings season winners and losers. In general, market results have been encouraging so far.

Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers)

NVIDIA and Eli Lilly are driving the bull market with their breakthrough technologies in AI and GLP-1s, respectively. LLY's strong Q1 and increased guidance suggest it could reach a $1 trillion market cap in the coming quarters if the company continues to grow into its deserved premium valuation. LLY's growth trajectory, strong new-product cycle, and pipeline make it a buy, with a potential fair value of $1,000 per share.

Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise

Eli Lilly reported strong Q1 results, with a 26% increase in revenues and a 59% increase in non-GAAP EPS. Management increased revenue guidance for 2024 due to strength in the GLP-1 franchise. Lilly's impressive pipeline includes potential treatments for obstructive sleep apnea, heart failure, Alzheimer's, and atherosclerotic cardiovascular disease.

Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise

iShares U.S. Pharmaceuticals ETF

iShares U.S. Healthcare ETF

Horizon Kinetics Medical ETF

VanEck Vectors Pharmaceutical ETF

Health Care Select Sector SPDR Fund

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

CRISPR Therapeutics

Viking Therapeutics

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so.

Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge

Coupang

Microsoft

NVIDIA

Stanley Druckenmiller has one of the best investing records out there. He worked closely with George Soros, helping to "break the Bank of England.

Nearly 50% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 4 Stocks

Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.

These 3 Companies Recently Lifted Guidance

Eli Lilly's non-GAAP earnings of $2.58 per share surpassed analysts' estimates. Revenue increased by 26% year over year, but still fell just short of analysts' expectations.

News for Eli Lilly Stock (LLY)